Speaker Profile


Gwendolyn Wise-Blackman

Principal Consultant, Gwen Wise-Blackman Consulting, LLC

Gwen Wise-Blackman, Ph.D. has over 20 years of combined experience in Cell-Based Assays and Quality Systems. She has worked at DuPont Pharmaceuticals, Catalent Pharma Solutions (formerly Magellan Laboratories and Cardinal Health), and Salix Pharmaceuticals where she successfully managed multiple projects and held positions of increasing accountability for scientific and quality expertise. Currently she is the owner of Gwen Wise-Blackman Consulting, LLC, a biopharmaceutical consulting firm.

Her focus has been in High-Throughput Screening, Cell-Based Assay Method Development and Validation, Ligand Binding Methods, Technology Transfer, GxP Regulations, Training, Audting, and Quality Assurance.

Dr. Wise-Blackman has a Bachelor of Science degree in biology from M.I.T and a PhD in Pharmacology from the University of Virginia. She is a member of ASQ and AAPS.

  •  Wednesday, May 8, 2019
  • 10:00 AM PDT | 01:00 PM EDT,
  • 60 Minutes
  • $150.00
Risk Evaluation and Mitigation Strategies

Pharmaceutical and biologic products often have adverse events (AE) that may not be identified until after approval and release.

  •  Wednesday, June 5, 2019
  • 10:00 AM PDT | 01:00 PM EDT,
  • 90 Minutes
  • $150.00
Implementing a Compliant Stability Program for Biologics

Biologics, as well as small molecule pharmaceutical products, require expiry dating.The complex structure of large molecules presents greater opportunities for degradation. Biologics may lose identity by cleavage ultimately resulting in loss of potency.

  •  Thursday, June 20, 2019
  • 10:00 AM PDT | 01:00 PM EDT,
  • 60 Minutes
  • $150.00
Auditing Laboratories Conducting Assays Supporting Biologics

Sponsors or consultants auditing labs on behalf of a pharmaceutical or biopharmaceutical company need strong tools for preparing and conducting audits.Careful consideration of the work that will be performed at the laboratory provides a working framework for the content of the audit.

View All



  • Recorded
  • View Anytime
  • 60 Minutes
  • $190.00
Risk Evaluation and Mitigation Strategies

Pharmaceutical and biologic products often have adverse events (AE) that may not be identified until after approval and release.

  • Recorded
  • View Anytime
  • 90 Minutes
  • $190.00
Implementing a Compliant Stability Program for Biologics

Biologics, as well as small molecule pharmaceutical products, require expiry dating.The complex structure of large molecules presents greater opportunities for degradation. Biologics may lose identity by cleavage ultimately resulting in loss of potency.

  • Recorded
  • View Anytime
  • 60 Minutes
  • $190.00
Auditing Laboratories Conducting Assays Supporting Biologics

Sponsors or consultants auditing labs on behalf of a pharmaceutical or biopharmaceutical company need strong tools for preparing and conducting audits.Careful consideration of the work that will be performed at the laboratory provides a working framework for the content of the audit.

  • Recorded
  • View Anytime
  • 60 Minutes
  • $390.00
Risk Evaluation and Mitigation Strategies

Pharmaceutical and biologic products often have adverse events (AE) that may not be identified until after approval and release.

View All

Payment Methods

Contact Us

NetZealous LLC,
161 Mission Falls Lane, Suite 216,
Fremont, CA 94539, USA.

Information

  Refund Policy
  +1-800-447-9407
  Fax: 302 288 6884
  support@compliance4All.com